288 related articles for article (PubMed ID: 37224424)
21. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
22. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
Jiang M; Li Q; Xu B
Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
[TBL] [Abstract][Full Text] [Related]
23. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A; Abdayem P; Adjei AA; Planchard D
Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
[TBL] [Abstract][Full Text] [Related]
24. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
[TBL] [Abstract][Full Text] [Related]
25. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
26. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
27. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
28. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.
Gerber HP; Koehn FE; Abraham RT
Nat Prod Rep; 2013 May; 30(5):625-39. PubMed ID: 23525375
[TBL] [Abstract][Full Text] [Related]
29. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
30. Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.
Sommer A; Berndt S; Lerchen HG; Forveille S; Sauvat A; Mumberg D; Kroemer G; Kepp O
Oncoimmunology; 2022; 11(1):2037216. PubMed ID: 35154909
[TBL] [Abstract][Full Text] [Related]
31. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
Hasan MM; Laws M; Jin P; Rahman KM
Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
[TBL] [Abstract][Full Text] [Related]
33. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
34. Antibody-Drug Conjugates: A Comprehensive Review.
Khongorzul P; Ling CJ; Khan FU; Ihsan AU; Zhang J
Mol Cancer Res; 2020 Jan; 18(1):3-19. PubMed ID: 31659006
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
Liu SN; Li C
Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of Resistance to Antibody-Drug Conjugates.
Loganzo F; Sung M; Gerber HP
Mol Cancer Ther; 2016 Dec; 15(12):2825-2834. PubMed ID: 27780876
[TBL] [Abstract][Full Text] [Related]
37. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L; Avancini A; Sposito M; Milella M; Rossi A; Pilotto S
Expert Opin Biol Ther; 2023; 23(11):1077-1087. PubMed ID: 36995069
[TBL] [Abstract][Full Text] [Related]
38. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
Nagayama A; Ellisen LW; Chabner B; Bardia A
Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
[TBL] [Abstract][Full Text] [Related]
39. Pushing the Envelope: Advancement of ADCs Outside of Oncology.
McPherson MJ; Hobson AD
Methods Mol Biol; 2020; 2078():23-36. PubMed ID: 31643047
[TBL] [Abstract][Full Text] [Related]
40. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
